# Mabgeek

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mabgeek

- Industry: Biotechnology
- Headquarters: Changsha, China
- Total disclosed funding: $43M
- Latest round: Series B (Aug 3, 2024)
- Investors on record: 11

## About

Based in Shanghai, China and established in 2016, Mabgeek is a biotech company that focused on research and development of antibody drugs. Dr. Chenghai Zhang, the founder and CEO of the company, served as R&D Director and Deputy Dean at CITIC Guojian. In 2017, the company launched an innovative antibody molecule development project. The company has a research and development team. It also has a 500-square-meter laboratory and 4 cell rooms, including 2 high-standard cell rooms that can construct stable production cell lines. In August 2024, the firm raised over CNY 200 million in a round of series B funding. In August 2025, Mabgeek raised CNY 260 million in Pre-IPO funding led by new investor China Medical System Holdings Limited with participation from GF Qianhe, XJSCI, Zhongshan Venture Capital.

Mabgeek focuses on developing innovative antibody drugs with high biological activity and druggability for key indications such as respiratory diseases, dermatitis, and nephropathy. The company's flagship product, MG-K10, is a monoclonal antibody targeting IL-4Ra.

The company generates revenue by providing innovative antibody drugs and services in the field of biomedicine, targeting allergic and autoimmune diseases.

The Pre-IPO financing will provide strong support for Maiji Bio's continued advancement in the research and development of innovative antibody drugs.

## Funding rounds

- Series B, Aug 3, 2024, $28M — Shandong Finance Investment Group, Tian Rui Feng Nian Private Fund, Kaiyuan Sichuang Investment, XJSCI, Zhangshu Youth Venture Capital
- Series A, Apr 9, 2021, $15M — Tronfund, Dynamic Capital, Sensegain Asset Management, Shanghai Zhangjiang Haoheng Venture Capital, Guangzhou Tianhui Capital Management
- Angel, Feb 17, 2017 — Huagai Capital

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Angel
- Tronfund (https://capitalatlas.ai/funds/tronfund) — Series A
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series A
- Sensegain Asset Management (https://capitalatlas.ai/funds/sensegain-asset-management) — Series A
- Shanghai Zhangjiang Haoheng Venture Capital — Series A
- Guangzhou Tianhui Capital Management — Series A
- Shandong Finance Investment Group (https://capitalatlas.ai/funds/shandong-finance-investment-group) — Series B
- Tian Rui Feng Nian Private Fund (https://capitalatlas.ai/funds/tian-rui-feng-nian-private-fund) — Series B
- Kaiyuan Sichuang Investment (https://capitalatlas.ai/funds/kaiyuan-sichuang-investment) — Series B
- XJSCI — Series B
- Zhangshu Youth Venture Capital (https://capitalatlas.ai/funds/zhangshu-youth-venture-capital) — Series B